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Abstract 
Background: Preclinical evaluations of chemotherapies depend on clinically relevant animal models for pancreatic 
cancer. The injection of syngeneic murine adenocarcinoma cells is one efficient option to generate carcinomas in 
mice with an intact immune system. However, this option is constrained by the paucity of appropriate cell lines.
Results: The murine pancreatic adenocarcinoma cell lines 6606PDA and 7265PDA were compared to the 6606l 
cell line isolated from a liver metastasis from mice suffering from pancreatic cancer. In tissue culture 6606PDA and 
6606l proliferated faster than 7265PDA. 7265PDA cells were, however, significantly more sensitive to gemcitabine as 
assessed by BrdU‑incorporation and trypan blue exclusion assays in vitro. Within 1 week after injection of either one of 
these three cell lines into the pancreas of C57BL/6J mice, carcinomas were observed by T2 weighted magnetic reso‑
nance imaging and histology. Three weeks after injecting 6606PDA or 6606l cells large carcinomas could be character‑
ized, which were surrounded by extensive desmoplastic reaction. After injection of 7265PDA cells, however, remission 
of cancer was observed between the first and the third week. Compared to 6606PDA cell derived carcinomas a higher 
apparent diffusion coefficient was quantified by diffusion weighted magnetic resonance imaging in these tumors. 
This correlated with reduced cancer cell density observed on histological sections.
Conclusion: All three cell lines can be used in vitro for testing combinatorial therapies with gemcitabine. The 
6606PDA and 6606l cell lines but not the 7265PDA cell line can be used for evaluating distinct therapies in a synge‑
neic carcinoma model using C57BL/6J mice. Diffusion‑weighted MRI proved to be an appropriate method to predict 
tumor remission.
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Background
Although multiple radiation therapies and chemotherapies 
in addition to surgical intervention have been evaluated 
over the last decades, the 5-year survival rate of pancreatic 
cancer patients is still only 7 % [1]. Recently, clinical stud-
ies demonstrated prolonged survival of patients after the 
application of novel combinatorial chemotherapies such 
as FOLFIRINOX or the combination of gemcitabine with 
nab-paclitaxel or S-1 [2–4]. However, these novel therapies 
can prolong the survival of patients only by a few weeks. 
Since progress in the treatment of pancreatic ductal ade-
nocarcinoma (PDA) has been modest, the evaluation of 
novel therapies and the investigation of all pathophysiolog-
ical aspects of PDA continue to be essential.
The evaluation of therapies in tissue culture along with 
the analysis in an orthotopic cancer model combines 
the advantages of in vitro studies with the advantages of 
a clinically relevant animal model [5, 6]. Tissue culture 
allows the evaluation of combinatorial therapies on iso-
lated cancer cells in a fast and cost efficient way, whereas 
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a syngeneic orthotopic cancer model allows the in  vivo 
evaluation of therapies while considering clinically rel-
evant factors such as a desmoplastic reaction, an intact 
immune system, and pharmacokinetic aspects of applied 
therapies [7]. It has been suggested that mice with ortho-
topically implanted syngeneic tumors are clinically more 
relevant than alternative animal models [7].
However, only few cell lines are available for PDA in a syn-
geneic orthotopic cancer model. Panc02 cells, derived from 
C57BL/6 mice after treating the animals with 3-methyl-cho-
lanthrene, were originally characterized more than 30 years 
ago [8]. These pancreatic adenocarcinoma cells have been 
used in many studies but have probably accumulated genetic 
changes over time in distinct laboratories. Recently, the 
need for additional carcinoma cell lines has been addressed 
by characterizing cancer cells, which were isolated from 
genetically modified mice with a C57BL/6 or mixed B6/129 
background [9, 10]. However, cells derived from a mixed 
background require the evaluation of histocompatibility of 
recipient mice [9]. The 6606PDA cell line, which is synge-
neic to the C57BL/6J mouse strain, has first been described 
in 2011 [11]. This cell line has been reported to gener-
ate more differentiated glandular adenocarcinomas than 
Panc02 cells when injected into the pancreas head [12].
The purpose of this study was to compare the charac-
teristics of two novel cell lines, 7265PDA and 66061, with 
6606PDA cells in  vitro. In addition, we evaluated these 
cell lines in a mouse model after orthotopic injection by 
analyzing tumor growth using magnetic resonance imag-
ing (MRI) at two different time points.
Results and discussion
Characterization of 6606PDA, 6606l, and 7265PDA cells 
in vitro
When plated on tissue culture dishes, the cells of the 
murine cell lines, 6606PDA and 6606l, showed a simi-
lar morphology. At low cell density these cells had a 
stretched fibroblast like appearance (Fig.  1a). However, 
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Fig. 1 Characterization of carcinoma cell lines in tissue culture. a Characteristic images of 6606PDA, 6606l, and 7265PDA cells grown on tissue cul‑
ture plates with partial epithelioid morphology (arrow). b Quantification of cell expansion of indicated cells lines by direct counting of cells (number 
of independent experiments: 4 for each cell line). c Quantification of cell expansion of indicated cells lines by WST‑1 assay. Significant differences 
(*P ≤ 0.009) between all three cell lines are indicated in the box plot (number of independent experiments: 6 for each cell line). Bar 50 μm
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when these cells could form intercellular contacts, their 
appearance changed to a distinct flat epithelioid mor-
phology (Fig.  1a). 7265 PDA cells preferentially showed 
a flat epithelioid morphology (Fig.  1a). Proliferation of 
these cells was quantified directly by counting them or 
indirectly by WST-Assay (Fig. 1b, c). When the cells were 
subconfluent, 6606PDA cells proliferated faster than 
6606l cells, whereas 7265PDA cells were the slowest to 
divide (Fig. 1b, c).
In order to evaluate if these cell lines are sensitive to 
gemcitabine, an established drug for chemoterapy, we 
treated all three cell lines with distinct concentrations 
of gemcitabine and quantified cell proliferation indi-
rectly by WST-assay (Fig. 2a, b) or directly by measuring 
gemcitabine [µM]





























































































Fig. 2 Inhibition of proliferation by gemcitabine. a Quantification of cell proliferation of 6606PDA, 6606l, and 7265PDA cells grown in media 
containing the indicated gemcitabine concentrations using WST‑1 assays. b Comparison of EC50 values for each indicated cell line as measured by 
WST‑1 assay. c Quantification of gemcitabine dependent cell proliferation of 6606PDA, 6606l, and 7265PDA cells using BrdU incorporation assays. 
d Presentation of EC50 values for each indicated cell line as measured by BrdU incorporation and comparison to published EC50 values from MIA 
PaCa‑2 cells [13]. Significant differences (*P = 0.001) and a tendentious difference (#P = 0.026) are shown in the box plots (number of independent 
experiments: n = 7 for 6606PDA; n = 8 for 6606l, n = 7 for 7265PDA in a and b; n = 7 for 6606PDA; n = 6 for 6606l, n = 6 in c and d)
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5-bromo-2′-deoxyuridine (BrdU) incorporation (Fig.  2c, 
d). A concentration dependent inhibition of proliferation 
was observed with all three cell lines using either assay 
(Fig.  2a, c). For 7265PDA cells, however, a lower half 
maximal effective concentration (EC50) of gemcitabine 
could be defined compared to those of 6606PDA or 6606l 
cells (Fig. 2b, d). All three cell lines exhibited EC50 values 
for gemcitabine similar to human cell lines such as MIA 
PaCa-2 cells [13]. We also quantified cell death of these 
cell lines after treatment with gemcitabine. Gemcitabine 
strongly induced cell death in all three cell lines (Fig. 3). 
Gemcitabine induced a higher percentage of dead 
cells in 7265PDA cells when compared to gemcitabine 
treated 6606PDA and 6606l cells (Fig. 3). This confirmed 
that 7265PDA cells are more sensitive to gemcitabine 
(Fig.  3). A lower percentage of dead cells was observed 
after gemcitabine treatment of 6606l cells when com-
pared to 6606PDA cells, although inhibition of prolif-
eration after gemcitabine was similar between 6606PDA 
and 6606l cells (Figs.  2, 3). Probably mutations, which 
limit cell death in response to gemcitabine, accumulated 
in the 6606l cell line. Due to the observed sensitivity to 
gemcitabine all three cell lines should be especially use-
ful in evaluating additional chemotherapeutical agents in 
combination with gemcitabine in future. Such preclinical 
studies have been published for several other cell lines 
such as AsPC-1, SUIT-2, MIA PaCa-2, or Panc02 cells 
[14–17].
Characterization of 6606PDA, 6606l, and 7265PDA cells 
in vivo
In order to evaluate, if these cell lines can be used in a 
syngeneic orthotopic pancreas carcinoma model, these 
cells were injected into the pancreas head of C57BL/6J 
mice on day 0 and the pancreata were analyzed during 
the early phase (on day 5–7) and during the late phase, 
on day 20 or 21 (Fig. 4a). After injection of either cell line 
an insignificant postoperative decline in body weight 
was observed, but no cachexia developed within 3 weeks 
(Fig. 4b). The blood glucose concentration was also stable 
throughout this study (Fig.  4c). These data suggest that 
within 3 weeks these cell lines cannot be used for exam-
ining cachexia or diabetes as paraneoplastic phenomena 
that have been suggested to occur in patients with pan-
creatic cancer [18, 19].
To monitor tumors, we assessed the pancreata of mice 
by 7 T MRI during the early phase (day 5 or 6) and dur-
ing the late phase of tumor growth (day 20). Carcinomas 
could be identified during the early phase irrespective 
of the cell line used (Fig. 5a). Carcinomas could also be 
identified easily during the late phase when 6606PDA 
and 6606l cells were injected. However, in most cases 
carcinomas could not be identified when 7265PDA cells 
were injected (Fig.  5b). We quantified this observation 
and noticed that after injecting a total number of 6 ani-
mals with 6606PDA cells 6 carcinomas could be identi-
fied during the early phase and 6 carcinomas during the 
late phase of tumor growth (Fig.  5c). When injecting 
a total number of 6 mice with 6606l cells 5 carcinomas 
could be identified during the early phase and 4 carcino-
mas during the late phase (Fig.  5c). The median tumor 
weight of 6606PDA and 6606l derived tumors on day 
21 was 126  mg (interquartile range 101–154  mg) and 
145  mg (interquartile range 25–208  mg), respectively 
(Fig. 5d). Thus, these two cell lines generate carcinomas 
in immunocompetent C57BL/6J mice and should be 
particularly valuable in studying various aspects of can-
cer immunology. When injecting a total number of 11 
mice with 7265PDA cells 8 carcinomas could be identi-
fied during the early phase of tumor growth and only 1 
carcinoma could be observed during the late phase with 
a tumor weight of 110 mg (Fig. 5c, d). Thus, seven mice 
have completely lost the tumor within 2  weeks. In this 
group the number of animals was increased to 11 mice 
in order to verify the reproducibility of the observed car-
cinoma remission. Macroscopic inspection of the pan-
creas after laparotomy of the animals verified that MRI 
accurately identified the presence or the absence of car-
cinomas. We also injected a total number of four immu-
nocompromised NMRI-Foxn1nu/nu mice with 7265PDA 
cells and observed that all mice developed carcinomas 
























Fig. 3 Induction of cell death by gemcitabine. a Quantification of 
cell death of 6606PDA, 6606l, and 7265PDA cells grown in unsup‑
plemented medium (Sham) or medium supplemented with 625 nM 
gemcitabine (Gem) using a trypan blue exclusion assay. Significant 
differences between indicated cohorts (*P ≤ 0.005); and significant 
differences between cells of the identical cell line (#P ≤ 0.001) grown 
in gemcitabine versus control medium are shown in the box plot 
(number of independent experiments: n = 10 for 6606PDA; n = 8 for 
6606l, n = 7 for 7265PDA)
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within 21 days (median tumor weight: 325 mg; interquar-
tile range 216–563  mg). The remission of carcinomas 
after injection of 7265PDA cells in C57BL/6J mice sug-
gests that this mouse strain is not syngeneic to this cell 
line. Indeed, information obtained from the laboratory 
of David Tuveson (Cambridge, UK) suggests that this 
cell line was isolated from a mouse with a mixed Bl6/129 
background. Thus, for 7265PDA cells the use of immuno-
compromised mouse strains or mice with matched histo-
compatibility will be mandatory.
To characterize differences between carcinomas 
derived from 6606PDA cells and 7265PDA diffusion-
weighted MRI was performed during the early phase 
of tumor growth (Fig.  6a). Interestingly the calculated 
apparent diffusion coefficient (ADC), measured at the 
edge of both classes of carcinomas, was higher in carci-
nomas derived from 7265PDA cells than in carcinomas 
derived from 6606PDA cells (Fig.  6b). This observa-
tion correlated well with the histology of these tumors. 
6606PDA cell derived carcinomas were characterized by 
many densely packed cancer cells (Fig.  6c upper panel). 
Inflammatory cells surrounded these carcinomas, but 
only few inflammatory cells were observed within these 
carcinomas (Fig. 6c upper panel). 7265PDA cell derived 
carcinomas were characterized by oedema, massive infil-
tration of inflammatory cells, and few loosely packed 
cancer cells (Fig.  6c lower panel). These data suggest 
that less than a week after injection of 7265PDA cells the 
immune system of C57BL/6J mice prevented the accu-
mulation of densely packed cancer cells. Instead, infil-
trating inflammatory cells lead to a local oedema which 
results in a higher ADC value when diffusion-weighted 
MRI was performed.
On day 21 cells with epithelial morphology could be 
observed in carcinomas derived from all three cell lines 
(Fig. 7a–c). All carcinomas were largely encapsulated by 
fibroblast like cells (Fig.  7d–f). On individual histologi-
cal sections of 6606PDA or 6606l derived tumors, the 
carcinomas lacked complete encapsulation by fibroblast 




















































Fig. 4 The Murine carcinoma model. a Experimental protocol: injection of carcinoma cells into the pancreas head on day 0, first MRI during early 
phase (day 5 or 6), second MRI during the late phase of tumor growth (day 20), and analysis of the tissue on day 7 or 21. b Mouse body weight at 
indicated time points after injection of 6606PDA, 6606l, or 7265PDA cells. c Blood glucose concentration at indicated time points after injection of 
6606PDA, 6606l, or 7265PDA cells. Number of animals analyzed: n = 6 for 6606PDA; n = 6 for 6606l, n = 11 for 7265PDA; 2 independent experi‑
ments
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growth of the cancer cells (Fig.  7g–h). A deficiency in 
encapsulation was not observed in the one carcinoma 
derived from 7265PDA cells (Fig. 7i). Consistent with the 
observation that infiltrative growth was hardly observed 
on day 21, we did also not detect any hepatic metastasis 
by macroscopic evaluation of the liver (data not shown). 
Since during the early phase (day 5 or day 6) the carci-
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Fig. 5 Characterization of carcinoma cell lines in vivo. a Characteristic T2‑weighted MRI of 6606PDA, 6606l, and 7265PDA cell derived carcinomas 
(arrows) during early phase of tumor growth (day 5/6). b Characteristic T2‑weighted MRI of carcinomas (arrows) during late phase of tumor growth 
(day 20). c Graphical presentation of the number of cell injections carried out and the number of detected tumors at the first MRI or the second 
MRI for 6606PDA, 6606l, and 7265PDA cells (number of mice analyzed: n = 6 for 6606PDA; n = 6 for 6606l, n = 11 for 7265PDA). d Comparison of 
tumor weight for indicated cell lines on day 21. Number of tumors analyzed: n = 6 for 6606PDA; n = 5 for 6606l, n = 1 for 7265PDA; 2 independent 
experiments
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encapsulated by fibroblast like cells (Fig. 6c, d, and data 
not shown), the development of desmoplasia could be 
studied in this animal model between day 6 and day 21.
Conclusion
The presented experiments describe the applicabil-
ity of the carcinoma cell lines 6606PDA, 7265PDA, and 
6606l for in vitro as well as in vivo studies. The data sug-
gest that (1) all three cell lines will be useful in studying 
novel combinatorial therapies in vitro using gemcitabine, 
(2) the 6606PDA and 6606l cells might be very suitable 
in studying various aspects of cancer immunology in 
C57BL/6J mice, and that (3) diffusion weighted MRI can 
be used to define immune mediated cancer rejection.
Methods
Cell culture
The murine cell lines, 6606PDA and 6606l, were isolated 
from pancreatic carcinoma or a liver metastasis detected 
in a mouse after p48-cre induced expression of the 
KRASG12D oncogene in the pancreas [20]. The 7265PDA 
cells were derived from a pancreatic carcinoma, which 
developed after pdx1-creER induced expression of 
p53R172H and KRASG12D. These three cell lines were a 
generous gift from Prof. Tuveson (Cambridge, UK) and 
were isolated in his lab according to Schreiber et al. [21]. 
Briefly, the tumors were dissected, minced, and digested 
at 37  °C in a Hank’s balanced salt solution contain-
ing 2 mg/mL type V collagenase (Sigma, St. Louis, MO, 
USA). The material was then filtered through nylon mesh 
and the protease was inactivated by the addition of Dul-
becco’s modified Eagle medium/F12 (Invitrogen, Carls-
bad, CA, USA) supplemented with 10  % fetal bovine 
serum. For all assays the cells were grown in DMEM high 
glucose medium (Biochrom GmbH, Berlin, Germany) 
with 10  % fetal calf serum on uncoated plastic dishes. 
Expansion of all three cells lines was quantified directly 
by plating 4 ×  103 cells per well in a 12 well plate and 
counting cells after 24, 48, 72, or 96 h. Expansion of cells 
was also determined indirectly by WST-assay after plat-
ing of 4 × 103 cells per well in a 96 well plate, growing the 
cells 48 h, and determining cell metabolism with the Cell 
Proliferation Reagent WST-1 (Roche Diagnostics, Man-

























Fig. 6 Characterization of carcinomas by diffusion‑weighted MRI and histology during the early phase of tumor growth. a Characteristic diffusion‑
weighted MRI of 6606PDA and 7265PDA cell derived carcinomas (day 5/6). b Quantification of water diffusion of 6606PDA and 7265PDA cell 
derived carcinomas by diffusion‑weighted MRI, as given by the ADC value. c characteristic haematoxylin/eosin (H/E) staining of histological sections 
of carcinomas during the early phase of tumor growth (dotted arrow pancreatic acinar cells, arrow cancer cells, arrowhead oedema with infiltrating 
inflammatory cells). A significant difference between indicated cohorts (*P = 0.01) is shown in the box plot (number of tumors analyzed: n = 4 for 
6606PDA, n = 6 for 7265PDA; 2 independent experiments). Bar 100 μm
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by gemcitabine 4  ×  103 cells per well were plated in a 
96 well plate, grown for 24 h, and treated with the indi-
cated concentration of gemcitabine and the BrdU labe-
ling reagent (Roche Diagnostics, Mannheim, Germany) 
for additional 24 h. The incorporation of BrdU was then 
quantified with the colorimetric Cell Proliferation ELISA 
(Roche Diagnostics). To evaluate induction of cell death 
by gemcitabine 3 × 104 cells per well were plated in a 24 
well plate, incubated for 24 h, and treated with 625 nM 
gemcitabine or medium lacking gemcitabine for addi-
tional 48 h. Cell death was then quantified by trypan blue 
staining solution (Life Technologies, CA, USA).
Animals and the syngeneic orthotopic carcinoma model
Male C57BL/6J and NMRI-Foxn1nu/nu mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME) 
and bred in our local animal facility. Mice were kept on 
water and standard laboratory chow ad  libitum and all 
experiments were executed in accordance with German 
legislation and the EU-directive 2010/63/EU. As pub-
lished previously, laparotomy was performed on anes-
thetized mice (1.2–2.5 % isoflurane), 2.5 × 105 carcinoma 
cells were injected (single injection per animal) into the 
pancreas head, and the abdominal cavity was closed by 
sutures [22]. For pain relief 5  mg/kg carprofen (Pfizer 
GmbH, Berlin, Germany) was injected (sc) before sur-
gery and 800 mg/L metamizol (Ratiopharm GmbH, Ulm, 
Germany) was added to the drinking water until eutha-
nasia of the mice. For sampling blood and tissues animals 
were anesthetized with 90 mg/kg ketamine (bela-pharm, 
Vechta, Germany) and 7  mg/kg xylazine (Bayer Health 
Care, Leverkusen, Germany).
Analysis of the blood and the tissue
Blood glucose concentrations were measured with the 
blood glucose meter Contour (Bayer Vital, Leverkusen, 
Germany) and the tissue was sampled on days defined in 





Fig. 7 Characterization of carcinomas by H/E staining during the late phase of tumor growth. a–c Histological images of carcinomas, which were 
derived from 6606PDA, 6606l, or 7265PDA cells, show cells with epithelial morphology on day 21 (arrows). d–f Representative histological images of 
carcinomas, which were derived from the indicated cell lines, show that the carcinomas are mostly encapsulated by fibroblast like cells (arrow-
heads). g–i In few locations lack of encapsulation was observed in 6606PDA (g) or 6606l (h) but not in 7265PDA (i) derived carcinomas (selected 
histological images). Number of tumors analyzed: n = 6 for 6606PDA; n = 5 for 6606l, n = 1 for 7265PDA (2 independent experiments). Bar 100 μm
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[23]. The histology of carcinomas was evaluated on 
haematoxylin and eosin (H/E) stained paraffin tissue 
sections.
Morphological and diffusion‑weighted 7 T MRI
MRI was performed on anesthetized (1.2–2.5  % isoflu-
rane) mice at day 5–6 and day 20. Animals were scanned 
in 7 T small animal MRI (ClinScan, 7.0 T, 290 mT/m gra-
dient strength) with a whole mouse body coil (Bruker, 
Ettlingen, Germany). The imaging protocol included 
morphological T2 weighted turbo spin echo (T2w-TSE) 
and diffusion weighted imaging (DWI). Tumor sizes were 
assessed in high resolution T2-weighted images of trans-
versal plane images (TR: due to respiratory gating approx. 
1900 ms; TE: 45.0 ms; FA: 180°; FoV: 40 mm × 40 mm; 
matrix: 240 × 320; voxel size: 0.16 × 0.125 × 0.7 mm3, 24 
slices, acquisition time: 9:46 min).
The ADC value was calculated from echo planar imag-
ing DWI-sequence (two b values, b1 = 0, b2 = 800) TR: 
9000  ms; TE: 85  ms; FA: 90°; FoV: 35  mm  ×  35  mm; 
matrix: 256 × 256; 10 slices of 0.7 mm per slice.
Analysis of MRI data
Images were analyzed employing Slicer3D (National 
Institutes of Health, Bethesda, Maryland, USA) and 
ImageJ (National Institutes of Health, Bethesda, Mary-
land, USA) for ROI placement during ADC evaluation. 
For evaluation of necrosis and vital tumor tissue T2w 
images and ADC-maps were superimposed. For each car-
cinoma the mean ADC of three ROIs, fitted to the outer 
tumor tissue rim, was calculated.
Statistics
Data presentation and statistics were performed as 
described previously [22, 23]. The significance of differ-
ences was evaluated using a Mann–Whitney rank-sum 
test followed by the correction for the accumulation of 
the α error by considering the number of meaningful 
comparisons. Differences with P ≤  0.05, divided by the 
number of meaningful comparisons, were considered to 
be significant.
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